| Name | Title | Contact Details |
|---|---|---|
Roberta Sanfelice |
Global HR Head - Vision Supply Chain | Profile |
Dave Turner |
Head of R&D, Contact Lens Platform | Profile |
Douglas Lilac |
Director R&D Process Development & Commercialization | Profile |
Xiao-Yu Song |
Global Head of Research & Development, Johnson & Johnson Vision | Profile |
R & J Engineering Corp is a Kitchener, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
DestinationRX is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. The Company has four product candidates in development. LJPC-501 is La Jolla’s proprietary formulation of angiotensin II for the potential treatment of catecholamine-resistant hypotension and hepatorenal syndrome. GCS-100 is La Jolla’s first-in-class galectin-3 inhibitor for the potential treatment of chronic kidney disease. LJPC-1010, La Jolla’s second-generation galectin-3 inhibitor, is a more potent and purified derivative of GCS-100 that can be delivered orally for the potential treatment of nonalcoholic steatohepatitis and other diseases characterized by tissue fibrosis. LJPC-401 is La Jolla’s novel formulation of hepcidin for the potential treatment of conditions characterized by iron overload, such as hemochromatosis and beta thalassemia
The Company is positioning itself to be one of the top three multi-state cannabis operators active in the U.S. legal cannabis and hemp sector. RWB is predominantly focusing its investments on the major US markets, including Michigan, Illinois, Massachusetts and California with respect to cannabis, and the US and internationally for hemp-based CBD products.